ASCL1 and neoplasm: The daily oral administration of HOC at 10 mg/kg in the NEPC NCI-H660 xenograft animal model effectively targeted the EPHA3–BRN2–EZH2–ASCL1–DLL3–SYP–CHGA signaling network, achieved 20% complete tumor regression and effectively suppressed NEPC progression and locoregional and distant recurrences.